Ladenburg Thalmann Cuts SeraCare Life Sciences (SRLS) to Neutral Following Q1 Earnings
Tweet
Share
E-mailGet Alerts SRLS Hot Sheet
Price: $4.01 --0%
Rating Summary:
0 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
0 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
An analyst at Ladenburg Thalmann just downgraded shares of SeraCare Life Sciences (NASDAQ: SRLS) from Buy to Neutral in a mid-day research note.
The downgrade follows Q1 results from SeraCare Thursday morning.
SeraCare shares were down nearly 9 percent to $3.69 at last check.
For more ratings news on SeraCare Life Sciences click here and for the rating history of SeraCare Life Sciences click here.
The downgrade follows Q1 results from SeraCare Thursday morning.
SeraCare shares were down nearly 9 percent to $3.69 at last check.
For more ratings news on SeraCare Life Sciences click here and for the rating history of SeraCare Life Sciences click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Movano (MOVE) Misses Q2 EPS by 195c
- Bernstein SocGen Group Reiterates Outperform Rating on JD.com, Inc (JD), 'very cheaply valued'
Create E-mail Alert Related Categories
DowngradesRelated Entities
Ladenburg Thalmann Financial Services, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
